Accomplished Believe or not the eventual start to Ph2 is a giving . The design has been in the works and is being worked on presently . The NMIBC Ph1b has accomplished safety and tolerability IMO . Now if I'm not mistaken an international multi centre Ph2 trial is costly , my common sense tells me TLT is better off with a JV that brings much needed capital , essential american/international expertize , recognition to help boost SP and even , maybe , attract/bring a highly qualified CEO . I find it very simple .....TLT has amazing science , big pharma wants great science . If a banker is willing to gamble why not a useful partner .
Cheers